Production method of cocktail dendritic cell vaccine

JP2023120134A5Active Publication Date: 2024-11-11DC-BIOTECH LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2022126870
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2022-08-09
Publication Date
2024-11-11
Estimated Expiration
2042-02-17

AI Technical Summary

Technical Problem

Existing dendritic cell vaccines do not consistently achieve sufficient therapeutic effects in cancer patients due to mismatched antigens and heavy physical burden, leading to suboptimal immune activation and potential complications.

Method used

A method for producing a cocktail dendritic cell vaccine that involves collecting monocytes from patients, dividing them into groups, pulsing with specific and non-specific ligands, and storing them to create personalized vaccines that synergistically activate immune cells, including NKT cells, helper T cells, and killer T cells.

Benefits of technology

The method enhances immune recognition and attack on cancer cells, achieving a synergistic therapeutic effect with reduced patient burden by optimizing antigen matching and immune activation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

To provide a cocktail dendritic cell vaccine with high anti-cancer effect by combining specific and non-specific immunotherapies, from a small amount of a blood component collected in a single blood draw from a patient.SOLUTION: A method for producing a patient-specific cocktail dendritic cell vaccine includes: a preparation step of preparing for blood component sampling from a patient; a blood component sampling step of performing blood component sampling to collect, in a single puncture, a predetermined amount of monocytes from a patient ready for blood component sampling; a division step of dividing, into multiple groups, the monocytes collected only from the patient or immature dendritic cells differentiated from the monocytes; a pulsing step of pulsing a different type of ligands into each group divided in the division step, optionally with different timing starting from the time of the division; and a storage step of storing each group into which the ligands are pulsed.SELECTED DRAWING: Figure 2
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method for producing a vaccine that activates immunity produced based on a patient's own cells and enhances the anti-cancer effect. A "cancer vaccine" aims to suppress the progression of cancer by enhancing the patient's "immunity against cancer" and further reduce / eliminate cancer cells remaining in the body. Most of the currently available "cancer vaccines" are not for cancer prevention but are for treatment purposes and are used in "immunotherapy against cancer".

Background Art

[0002] In recent years, immunotherapy against cancer has been increasingly recognized as a practical treatment method alongside other surgical therapies, chemotherapy, and radiotherapy. Immunotherapy against cancer is a method of enhancing the attack of the immune system against cancer by strengthening the body's immunity or making cancer cells recognized by immune cells as targets for attack. So far, BRM therapy, cytokine therapy, cellular immunotherapy, vaccine therapy, etc. have been carried out. In particular, since the 2000s, vaccine therapy using dendritic cells has been carried out and has shown high efficacy. Here, each immunotherapy will be briefly described.

[0003] BRM (biological response modifier) therapy is an early treatment method represented by the Maruyama vaccine, which is a treatment method using substances that modify the patient's biological responsiveness to tumor cells, etc. As BRMs, PSK, bestatin, OK-432, etc. are known. Although the effectiveness of this treatment method has been recognized in some cancers, etc., it has a strong aspect of being an adjuvant therapy that can obtain effects by being used in combination with other treatment methods that reduce immune function, such as surgical therapy and chemotherapy. In addition, there is a problem that immunity is not necessarily enhanced, and the anti-cancer effect, etc. when used alone is weak.

[0004] Cytokine therapy is a treatment method that kills cancer cells or virus-infected cells by directly administering cytokines into the body that proliferate or activate lymphocytes such as T cells and NK cells. For example, cytokine therapy using interleukin-2 (hereinafter referred to as "IL-2") falls under this category. However, this therapy has not yielded the expected results in clinical outcomes and has also had problems such as causing serious side effects such as organ failure and fluid retention (in the case of IL-2 administration), and cold-like symptoms and mental disorders (in the case of interferon: IFN administration).

[0005] Cellular immunotherapy is a treatment method that enhances a patient's immunity by activating and proliferating immune cells taken from the patient outside the body and then returning them to the patient's body. It is also called "adoptive immunotherapy (adoptive immunotherapy in a broad sense)." Adoptive immunotherapy in a narrow sense is classified into activated lymphocyte therapy and NK cell therapy depending on the type of immune cells processed outside the body.

[0006] Activated lymphocyte therapy is further classified into two types: activated lymphocyte therapy in the narrow sense (activated T lymphocyte therapy), which involves activating and proliferating T cells outside the body, and activated NK cell therapy, which involves activating and proliferating NK cells.

[0007] Vaccine therapy is currently divided into peptide vaccines and dendritic cell vaccines. Peptide vaccines involve directly administering peptides that serve as markers for cancer into the body as antigens. Immune cells react to these antigens, recognizing cancer as a target for attack, thereby suppressing cancer. Dendritic cell vaccines, on the other hand, involve administering antigen-presenting cells called dendritic cells that carry antigens that serve as markers for cancer into the body. This activates killer T cells and helper T cells, thereby increasing their ability to attack cancer. Current research suggests that dendritic cell vaccines, which use dendritic cells to present antigens, are more effective than peptide vaccines, which directly administer antigens. The present invention provides a method for producing a cocktail dendritic cell vaccine, which involves dividing monocytes of equivalent condition (with little variation in monocyte quality) collected in a single blood collection cycle to produce multiple types of dendritic cell vaccines of equivalent condition.

[0008] Dendritic cell vaccines are created by culturing monocytes collected from a patient's blood into immature dendritic cells, adding a ligand (sometimes called an antigen) (this process is sometimes referred to as "pulsing"), and culturing the cells until they mature into dendritic cells that present a specific antigen. This dendritic cell vaccine therapy can also be divided into specific immunotherapy and nonspecific immunotherapy, depending on the antigen used.

[0009] <Specific immunotherapy> Specific immunotherapy for cancer involves producing an appropriate amount of dendritic cells in vitro, using the patient's own cells as the origin and employing antigens that serve as ligands for cancer markers. These dendritic cells are then used as a vaccine, causing killer T cells and helper T cells to recognize and attack cancer cells. A representative ligand used is the WT1 peptide, which has proven effective against a wide range of cancers. This is supported by the fact that the WT1 gene has been confirmed to be expressed as an antigen in various solid malignancies, including leukemia, lung cancer, colorectal cancer, pancreatic cancer, bone and soft tissue sarcoma, and malignant glioma. Therefore, using a vaccine that uses the WT1 peptide as a ligand to enable dendritic cells to retain it means that it can be used to treat a wide variety of cancers.

[0010] <Non-specific immunotherapy> Nonspecific immunotherapy is a treatment method aimed at strengthening the overall immune system. While BRM therapy and cytokine therapy are also classified as nonspecific immunotherapies, dendritic cell vaccines use α-galactosylceramide, an NKT cell activating ligand, to activate NKT cells, and a high immune-activating effect has been confirmed.

[0011] NKT cells, sometimes called the fourth type of lymphocyte, are a type of T cell that also possesses the characteristics of NK cells. NKT cells are activated by the presentation of glycolipid antigens and produce various cytokines, thus inducing both immunostimulatory and immunosuppressive responses. Immunostimulation strengthens the immune system's defenses against external threats, while immunosuppression reduces excessive immune responses and inflammation. Maintaining a balance between these two actions is essential for maintaining a healthy state. Furthermore, NKT cells can induce cell death in cancer cells and possess various anti-cancer effects, although their direct attack effect against cancer is low. Therefore, the anti-cancer effects of NKT cells are expected to be secondary effects mediated through other immune cells.

[0012] The following six aspects explain the anti-cancer effects of NKT cells.

[0013] (1) Maturation of dendritic cells As dendritic cells mature, they present cancer antigens to immune cells, thereby promoting the attack against cancer. However, immunosuppressive cells and substances produced by cancer can prevent dendritic cells from maturing, reducing their cancer-suppressing effect. The cytokines produced by NKT cells help mature dendritic cells, thereby enhancing the immune function against cancer.

[0014] (2) Adjuvant action It releases a substance called cytokine (IFN-γ), which activates and proliferates various immune cells. Against cancer, it has an inhibitory effect by activating killer T cells, NK cells, and macrophages.

[0015] (3) Direct killing effect against cancer cells Activated NKT cells have the effect of inducing apoptosis, a type of cell death in cancer cells.

[0016] (4) Checkpoint inhibitory effect Immune cells possess receptors called immune checkpoints, which suppress excessive immune responses. Cancer cells utilize this mechanism to produce immunosuppressive cells (cells with immune checkpoint inhibitory function that produce immune checkpoint molecules or their ligands) to evade attack by immune cells. However, killer T cells have the effect of killing these immunosuppressive cells, thus releasing the immunosuppression. Consequently, the attack of cancer cells by killer T cells is promoted, inducing an anti-cancer effect.

[0017] (5) Inhibition of angiogenesis It inhibits the process by which cancer tissue forms new blood vessels to supply nutrients and oxygen for growth. This prevents cancer cells from obtaining nutrients, thus suppressing their proliferation.

[0018] (6) Long-term immunological memory NKT cells can retain their ability to attack cancer cells for a long period of time by differentiating into memory-like NKT cells with immune memory function through the induction of CD1d-expressing cells.

[0019] As described above, immunotherapy targeting NKT cells is a relatively new treatment method among cancer immunotherapies that is expected to strengthen overall immunity.

[0020] Thus, various immunotherapies for cancer have been developed and improved, and there are many methods for manufacturing vaccines. For example, Patent Document 1 describes a method for producing a high-quality dendritic cell vaccine by including dendritic cells and zinc at a concentration of 200 ng / mL to 400 ng / mL, thereby increasing the cell viability of the dendritic cells by 10% compared to when they are washed with physiological saline. Furthermore, these dendritic cells are matured by adding cancer antigens containing WT1 peptide, thereby enhancing the anti-cancer effect as a dendritic cell vaccine that constitutes specific immunotherapy.

[0021] Furthermore, in Patent Document 2, an NKT cell activation ligand containing α-galactosylceramide is added to dendritic cells and matured to produce a dendritic cell vaccine. This is a method for producing a dendritic cell vaccine that is a non-specific immunotherapy for activating a wide range of immune cells.

Prior Art Documents

Patent Documents

[0022]

Patent Document 1

Patent Document 2

Summary of the Invention

Problems to be Solved by the Invention

[0023] However, clinical studies are being conducted on both dendritic cell vaccines disclosed in Patent Document 1 and Patent Document 2, and high effects are being confirmed compared to conventional immunotherapies. However, the expected effects are not necessarily obtained in all cancer patients. This is because dendritic cell vaccines become vaccines for various cancers and diseases depending on the antigen used. However, it can be said that sufficient effects cannot be obtained unless the vaccine has an antigen suitable for the patient's symptoms.

[0024] For example, when performing specific immunotherapy using the dendritic cell vaccine of Patent Document 1, even if the cancer recognition ability of lymphocytes is enhanced, sufficient effects may not be obtained because the overall immunity of the patient himself / herself is reduced, or the patient may die due to other diseases caused by complications, and the treatment effect may not appear.

[0025] In addition, when performing non-specific immunotherapy using the dendritic cell vaccine of Patent Document 2, although the immune function of the patient is improved, the anti-cancer effect is not necessarily exerted. This is because if the patient's immune system does not recognize cancer as an attack target, a sufficient anti-cancer effect cannot be obtained, and as a result, it may not appear as a cancer treatment effect.

[0026] In other words, the simultaneous progression of two actions is crucial: activating and proliferating various immune cells responsible for the body's immunity, and then ensuring that cancer cells, the target of attack, are clearly recognized by the specific immune system. Furthermore, reducing the burden on cancer patients is crucial for activating the immune system, yet many conventional cancer therapies impose heavy physical burdens on patients. It is important to note that cancer patients using immunotherapy often have advanced-stage cancer, and their remaining time and physical strength are often limited. To produce dendritic cell vaccines, it is necessary to collect and differentiate the patient's own monocytes, which requires apheresis. However, apheresis involves separating monocytes from blood drawn from the patient's body using an apheresis device and then returning it to the patient's body. This process is time-consuming and can cause side effects due to the addition of anticoagulants to the blood. Therefore, it is desirable to achieve the maximum effect with the blood collected in a single draw and allow the patient to recover to a degree where further treatment is possible.

[0027] In view of these circumstances, the present invention aims to provide a cocktail dendritic cell vaccine that offers a synergistic therapeutic effect for various cancer patients and provides hope for recovery by simultaneously performing two actions: activating and proliferating (this point is important) various immune cells responsible for the body's immunity through nonspecific immunotherapy, and then clearly recognizing target cancer cells by the specific immune system through specific immunotherapy. [Means for solving the problem]

[0028] The present invention relates to a method for producing a cocktail dendritic cell vaccine that activates a patient's immune system. The first invention comprises a preparation step of preparing to collect blood components from a patient; a blood component collection step of collecting a predetermined amount of monocytes from a patient ready for blood component collection in a single puncture (meaning that the predetermined amount of blood collection is completed in one cycle; multiple punctures are not prevented); a division step of dividing the monocytes or immature dendritic cells differentiated from monocytes collected only from the patient into multiple groups; a pulsing step of pulsing each group divided in the division step with a different type of ligand, possibly at different timings starting from the time of division; and a storage step of storing each group that has been pulsed with ligand, thereby providing a method for producing a patient-specific cocktail dendritic cell vaccine.

[0029] Furthermore, the cocktail dendritic cell vaccine of the second invention, in addition to the first invention, includes an immunity / disease information acquisition step in which one or more of the following are obtained before the preparation step: immunity information, which is information about the patient's immune system; the patient's individual biological information; and the patient's disease information; and a ligand selection step in which the ligand to be pulsed in the pulse step is selected according to the acquired immunity / disease information, thereby producing a cocktail dendritic cell vaccine tailored to the patient.

[0030] Furthermore, the cocktail dendritic cell vaccine of the third invention, in addition to the second invention, further comprises a division ratio determination step in which the division ratio of the division step is determined according to the acquired immunity and disease information, thereby producing the cocktail dendritic cell vaccine.

[0031] Furthermore, the cocktail dendritic cell vaccine of the fourth invention, in addition to the second or third invention, further comprises a storage period determination step in which the storage period of each group in the storage step is determined according to the acquired immunity and disease information, thereby manufacturing the cocktail dendritic cell vaccine.

[0032] Furthermore, the cocktail dendritic cell vaccine of the fifth invention further comprises, in addition to any one of the first to fourth inventions, an observation result acquisition step in which each group pulsed with ligand after the pulse step is observed and observation results are obtained, thereby producing the cocktail dendritic cell vaccine.

[0033] Furthermore, the cocktail dendritic cell vaccine of the sixth invention, in addition to any one of the first to fifth inventions, is manufactured by further determining the storage period of each group in the storage step according to the observation results obtained in the observation result acquisition step.

[0034] Furthermore, the seventh invention, a cocktail dendritic cell vaccine, is a method for producing a cocktail dendritic cell vaccine that, in addition to any one of the first to sixth inventions, includes a freezing / refrigeration storage step in which at least one of the groups divided between the division step and the pulping step is frozen or refrigerated.

[0035] Furthermore, the cocktail dendritic cell vaccine of the eighth invention further comprises, in addition to any one of the first to seventh inventions, a ligand generation step that generates ligands based on the individual patient's body tissue, and the pulse step is configured to pulse the ligands generated in the ligand generation step, thereby producing the cocktail dendritic cell vaccine.

[0036] Furthermore, the cocktail dendritic cell vaccine of the ninth invention, in addition to any one of the first to eighth inventions, has a filling step of filling an injection device (including but not limited to a syringe; the same applies hereinafter) for returning each pulsed group of ligands that have been stored after the storage period back into the patient's body in group units, thereby manufacturing the cocktail dendritic cell vaccine.

[0037] Furthermore, the cocktail dendritic cell vaccine of the tenth invention is characterized in that, in addition to any one of the first to ninth inventions, the ligands pulsed in the pulse step are WT1 peptide and two or more ligands selected from α-galactosylceramide and neoantigens, thereby producing a cocktail dendritic cell vaccine. [Effects of the Invention]

[0038] The present invention provides a method for producing cocktail dendritic cell vaccines, which offers the excellent advantage of being able to generate multiple dendritic cell vaccines with high cancer treatment efficacy using a limited number of blood components. [Brief explanation of the drawing]

[0039] [Figure 1] Summary of the present invention's method for producing cocktail dendritic cell vaccines. [Figure 2]This figure shows an example of the effect of a dendritic cell vaccine produced by the cocktail dendritic cell vaccine production method of the present invention on immunity. [Figure 3] Flowchart showing the manufacturing method for the cocktail dendritic cell vaccine according to Embodiment 1 [Figure 4] Flowchart showing the manufacturing method for the cocktail dendritic cell vaccine according to Embodiment 2 [Figure 5] Flowchart showing the manufacturing method for the cocktail dendritic cell vaccine according to Embodiment 3 [Figure 6] Flowchart showing the manufacturing method for the cocktail dendritic cell vaccine according to Embodiment 4 [Figure 7] Flowchart showing the manufacturing method for the cocktail dendritic cell vaccine according to Embodiment 5 [Figure 8] Flowchart showing the manufacturing method for the cocktail dendritic cell vaccine according to Embodiment 7 [Figure 9] Flowchart showing the manufacturing method for the cocktail dendritic cell vaccine according to Embodiment 8 [Figure 10] Flowchart showing the manufacturing method for the cocktail dendritic cell vaccine according to Embodiment 9 [Figure 11] This diagram shows an example of a table used to determine the division ratio in the division step. [Figure 12] Figure 1 shows an example of the storage period determined by the storage step. [Figure 13] Figure 2 shows an example of the storage period determined by the storage step. [Figure 14] Table rating the anti-cancer effects of dendritic cell vaccines. [Modes for carrying out the invention]

[0040] First, before describing embodiments of the present invention, we will explain the body's immune system. Immunity can be divided into innate immunity, which organisms are born with, and acquired immunity, which is acquired later in life.

[0041] Innate immunity is the immune system that is present in the human body from birth and is primarily composed of phagocytic cells that engulf and eliminate foreign substances such as bacteria and viruses. Phagocytic cells have receptors that recognize molecules and structures and can be broadly classified into two types: those that process and eliminate foreign substances and those that play a role in transmitting signals within the cell. Examples of immune cells include eosinophils, neutrophils, basophils, macrophages, dendritic cells, and NK (natural killer) cells.

[0042] On the other hand, adaptive immunity is a mechanism that remembers pathogens that have infected the body, enabling it to effectively eliminate them when encountered again. Compared to innate immunity, it takes longer to respond, but it has the versatility to respond to various pathogens. Immune cells include B cells and T cells, and T cells are further divided into helper T cells, killer T cells, and regulatory T cells. B cells can change into plasma cells and memory B cells depending on the situation.

[0043] Furthermore, there are NKT cells that possess the properties of both innate and adaptive immunity. Among the immune cells mentioned above, the cells that this cocktail dendritic cell vaccine directly acts on are NKT cells, helper T cells, and killer T cells. However, the activation of these cells also activates other cells such as NK cells, macrophages, dendritic cells, and B cells.

[0044] Hereafter, we will briefly explain the immune cells and substances related to immune function involved in the action of the dendritic cell vaccine produced by this cocktail dendritic cell vaccine manufacturing method.

[0045] <Explanation of terms related to immune cells and substances involved in immune function> <Explanation of terminology: antigen> These are foreign substances that enter the body and serve as markers for acquired immune cells to recognize as targets for attack. In the case of cancer antigens, immune cells recognize them as targets for attack based on the structure of proteins that are not present in normal cells.

[0046] <Glossary: ​​Antibody> Immunoglobulins are a general term for proteins, and cancer antibodies bind to cancer cells and attack them through the following three mechanisms. Neutralizing effect: An effect that inhibits the proliferation of cancer cells. ADCC activity: Acts as a marker for killer T cells and NK cells, assisting in the attack of cancer. CDC activity: Activates complement and damages cancer cells.

[0047] <Explanation of terminology: cytokines> Cytokines are proteins secreted by immune cells and are a general term for physiologically active substances involved in intercellular interactions. They transmit signals to target cells, triggering various cellular responses such as cell activation, cell proliferation, differentiation, cell death, and functional expression. Interferons and interleukins are classified as cytokines.

[0048] <Glossary: ​​Interleukin> Interleukins, a type of cytokine, currently number over 30. They are secreted in large quantities, particularly by lymphocytes (a type of white blood cell that fights foreign substances in the body) and phagocytic cells such as macrophages and neutrophils.

[0049] <Glossary: ​​Interferon> Interferon, a type of cytokine, activates NK cells and macrophages, which attack cancer cells and virus-infected cells, and suppresses the proliferation of viruses and tumor cells. It is approved in Japan as an antiviral and anticancer drug and is used to treat multiple myeloma, brain tumors, and kidney cancer.

[0050] <Glossary: ​​NK cells> NK cells possess various receptors that can detect abnormal cells, and they have the effect of damaging cells that they recognize as abnormal, such as virus-infected cells and cancer cells.

[0051] <Glossary: ​​Macrophage> Macrophages are a type of white blood cell that are activated by signals from biological tissues and environmental stress, and they engulf foreign substances such as bacteria. They are also antigen-presenting cells that present the engulfed foreign substances as antigens to helper T cells, and when they take in antigens, they produce the cytokine (IL-12). They are also activated by cytokines (IFN-γ) produced by helper T cells.

[0052] <Glossary: ​​Dendritic cell> These are antigen-presenting cells that take in foreign substances and present the antigens to T cells, allowing them to recognize the substance as a target for attack. Early dendritic cells are called immature dendritic cells because they possess the ability to take in antigens (phagocytosis).

[0053] <Glossary: ​​Helper T cell> Upon being presented with an antigen, it is recognized as a target for attack and instructs killer T cells to attack. It also produces substances called cytokines that activate B cells, and together with B cells, it helps determine whether a foreign substance is dangerous and assists in antibody production.

[0054] <Glossary: ​​Killer T cell> Killer T cells recognize antigens presented by MHC class I molecules and damage those cells. Thus, the T cell response, which is part of acquired immunity, begins with antigen presentation of antigen peptides by MHC molecules. Under the direction of helper T cells, cells that are dangerous or unnecessary to the body, such as virus-infected cells or cancer cells, are killed and removed.

[0055] <Glossary: ​​B cell> Stimulated by cytokines produced by helper T cells, antibodies are generated. Even after the antigen is eliminated, memory B cells remember the antigen and prepare for future invasions.

[0056] <Glossary: ​​NKT cells> These cells possess characteristics of both T cells and NK cells. When activated, they produce cytokines (IFN-γ) and also have the function of inducing the response to immunostimulatory and immunosuppressive therapies. Furthermore, the most anticipated effect of this invention is its adjuvant effect, which activates various immune cells in the body and, importantly, promotes their proliferation.

[0057] <Overview of Cocktail Dendritic Cell Vaccines> Next, using Figures 1 and 2, we will explain the outline of the cocktail dendritic cell vaccine manufacturing method of the present invention and the mechanism by which this cocktail dendritic cell vaccine enhances immunity.

[0058] Figure 1 shows an overview of the cocktail dendritic cell vaccine production method of the present invention. This cocktail dendritic cell vaccine is cultured using the patient's own cells and is therefore a highly safe vaccine with no risk of rejection, as it is tailored specifically for each patient. First, monocytes are collected from the patient using apheresis. "Component aspiration" is a method of blood collection in which blood is taken out of the body using a medical tube or similar device, and the target blood components and factors are separated from the blood using specialized equipment and then returned to the body. In this invention, monocytes are separated as the blood component, and approximately 100cc of blood components are collected. In addition to monocytes, the blood components after monocyte separation also include plasma and platelets. Component aspiration places a significant burden on the body because it involves mixing an anticoagulant into the blood before monocyte separation to prevent blood clotting, and then returning that anticoagulant to the body, as well as the long duration of the component aspiration process for monocyte separation.

[0059] Next, monocytes from collected blood are cultured with cytokines to induce differentiation into immature dendritic cells. Subsequently, the cultured immature dendritic cells are separated into two or more containers. A ligand used for specific immunotherapy is added to one container, and a ligand used for non-specific immunotherapy is added to the other. Both containers are then cultured to mature into dendritic cells. In this way, dendritic cells cultured with antigens are produced as dendritic cell vaccines targeting specific diseases.

[0060] The quality of the cultured dendritic cell vaccine is visually inspected using a microscope or other means. The quality of a dendritic cell vaccine includes factors such as the survival rate of dendritic cells, the morphology of the dendritic cells (e.g., whether they have many branches), and whether they are free from contamination by bacteria or fungi. Dendritic cell vaccines whose quality and safety have been confirmed are stored in storage containers. They are then administered according to the patient's condition. The above is an overview of the method for producing the cocktail dendritic cell vaccine of the present invention. As described above, the method for producing the cocktail dendritic cell vaccine of the present invention makes it possible to generate combinations of multiple dendritic cell vaccines that are expected to have a high anti-cancer effect from blood components collected by a single puncture procedure from a patient. Although it is called a cocktail dendritic cell vaccine, in this invention, "cocktail" means that the dendritic cell vaccine administered to the patient is two or more types of dendritic cell vaccines. In addition to administering two or more types of dendritic cell vaccines after mixing them in advance, the procedure for administering multiple types of dendritic cell vaccines may also involve administering each type individually. Furthermore, when using three or more types of dendritic cell vaccines, it is also possible to administer two or more types of dendritic cell vaccines mixed together and then administer the remaining dendritic cell vaccines one by one.

[0061] <Mechanism of Action of Cocktail Dendritic Cell Vaccines> Figure 2 shows an example of using two types of dendritic cell vaccines produced by the cocktail dendritic cell vaccine production method of the present invention. The thickest arrows in the figure (0201, 0210) indicate the direct effects on pre-existing immune cells in the body of two different types of dendritic cell vaccines: one pulsed with the ligand α-galactosylceramide, and the other pulsed with the ligand WT1 peptide. The second thickest arrows (0202, 0203) indicate that activated NKT cells act particularly strongly compared to the effects of other activated NKT cells. The thin arrows indicate the effects of immune cells in the body in response to the dendritic cell vaccines. The ellipses represent immune cells described within the ellipse, and the triple ellipse represents immune cells that are particularly enhanced by the cocktail dendritic cell vaccine. The polygon in the center represents cancer cells. The dashed lines around the cancer cells indicate the immunosuppressive effect of cancer cells, showing that they form a barrier from the immune system. The depiction of blood vessels indicates that cancer cells obtain nutrients from blood vessels through angiogenesis. Next, we will explain each function, referring to the numbered sections.

[0062] <Effects of alpha-galactosylceramide-pulsed dendritic cell vaccine: Activation of NKT cells: 0201> Dendritic cell vaccines pulsed with alpha-galactosylceramide activate NKT cells. Activated NKT cells exert various effects on immune function. The following explains the five main effects within that context.

[0063] <Effects of activated NKT cells 1: Promotion of dendritic cell maturation: 0202> Activated NKT cells produce cytokines that promote the maturation of immature dendritic cells in the body.

[0064] <Actions of activated NKT cells 2: Adjuvant action: 0203> Activated NKT cells produce cytokines (IFN-γ), which activate NK cells, macrophages, and killer T cells, thereby enhancing their ability to attack cancer. They also activate various other immune cells. Killer T cells and helper T cells are activated by pulsing dendritic cells with the WT1 peptide, a specific immune activity, as a ligand. These activated NK cells and activated B cells simultaneously receive beneficial effects through nonspecific immune activity pathways, resulting in a 1+1>2 effect, or synergistic effect. This is one of the features of the present invention.

[0065] <Effects of activated NKT cells 3: Inducing apoptosis in cancer cells: 0204> Activated NKT cells produce a type of serine protease that degrades the DNA of cancer cells, thereby inducing apoptosis in cancer cells.

[0066] <Action of activated NKT cells 4: Checkpoint inhibitory effect: 0205> Activated NKT cells kill immunosuppressive cells that cancer cells prepare to protect themselves from attacks by the body's immune cells. This releases various forms of immunosuppression, significantly improving the immune state within cancer tissue. For example, it allows killer T cells to effectively attack cancer cells. In this way, checkpoint inhibition based on nonspecific immune activity further amplifies the cancer-attacking ability of killer T cells based on specific immune activity. This point, like the adjuvant effect described, is one of the features of this invention where a 1+1>2 effect, or synergistic effect, is obtained.

[0067] <Effects of activated NKT cells 5: Inhibitory effect on angiogenesis: 0206> Activated NKT cells inhibit angiogenesis, which cancer cells use to obtain nutrients, making it difficult for cancer cells to acquire nutrients and thus suppressing the proliferation of cancer cells.

[0068] <Actions of activated macrophages: Phagocytosis of cancer cells by macrophages: 0224> Activated macrophages phagocytose cancer cells and cancer dead cells.

[0069] <Effect of dendritic cell vaccine pulsed with WT1 peptide: Cancer antigen presentation effect: 0210> Dendritic cell vaccine pulsed with WT1 peptide presents and activates the WT1 peptide, which is a cancer antigen, to helper T cells and killer T cells. As a result, killer T cells recognize cancer cells as targets for attack, helper T cells activate killer T cells, and further activate NK cells as described below by producing cytokines, and promote B cells to produce antibodies.

[0070] <Effect of activated helper T cells: Instruction for attacking cancer cells: 0211> Activated helper T cells produce cytokines (INF-γ) and instruct killer T cells to attack cancer cells based on the information contained in the cytokines. In addition, the effects of cytokines activate NK cells, B cells, and macrophages, enhancing the attack on cancer.

[0071] <Effect of activated helper T cells: Instruction for antibody production against cancer antigen (e.g., WT1): 0212> Activated helper T cells produce cytokines and instruct B cells to produce antibodies against cancer antigens (e.g., WT1) based on the information contained in the cytokines.

[0072] <Effect of activated killer T cells: Attack on cancer cells by killer T cells: 0213> This is the main action of directly attacking cancer cells. Activated killer T cells recognize and bind to WT1 expressed on cancer cells, create holes in the cell membrane, and cause cancer cells to necrotize. Furthermore, substances such as TNF-β (tumor necrosis factor, a type of cytokine) are produced to induce apoptosis of cancer cells. Thus, the direct attack of killer T cells on cancer cells is a powerful anti-cancer action that attacks cancer cells from both the outside and the inside.

[0073] <Action of activated killer T cells: Neovascularization effect: 0214> Blood vessels newly formed by cancer cells express the WT1 gene, and killer T cells presented with the cancer antigen (WT1) attack not only the cancer cells but also the newly formed blood vessels. As a result, the new blood vessels are destroyed, reducing the supply of nutrients to the cancer cells and suppressing their proliferation. This effect is also one of the factors that contribute to the 1+1>2 effect of the cocktail dendritic cell vaccine of the present invention.

[0074] <Actions of activated NK cells: Attack of cancer cells by NK cells: 0220> Activated NK cells exhibit a cytotoxic response against cancer cells, attacking them.

[0075] <Actions by proliferating and activated macrophages: Antigen presentation action by macrophages 0222> Activated NKT cells proliferate and activate macrophages. These proliferated and activated macrophages engulf cancer cells through phagocytosis, fragment them, and present them on their cell surface. In other words, they exhibit an antigen-presenting function, displaying the antigens of cancer cells. These presented antigens are transmitted to dendritic cells, enabling the dendritic cells to further present antigens.

[0076] <Dendritic cell cancer antigen presentation effect: 0221> Immature dendritic cells take up cancer antigens, mature, and differentiate into mature dendritic cells, which then present cancer antigens to helper T cells and killer T cells. This effect is a normal anti-cancer effect that can occur in the body, but the action of activated NKT cells results in an even greater anti-cancer effect than usual. Since this cancer antigen is an antigen presented when macrophages phagocytose the patient's own cancer cells, it is expected to be more effective than dendritic cell vaccines that use artificial antigens as ligands. This effect is also one of the factors that contribute to the 1+1>2 effect of the cocktail dendritic cell vaccine of the present invention.

[0077] <Action of activated B cells: Cancer antibody production: 0223> Activated B cells produce antibodies against cancer antigens (e.g., WT1) and attack cancer cells. These antibodies have various effects, such as suppressing the proliferation of cancer cells by binding to them, or acting as markers for other immune cells (e.g., NK cells and killer T cells) to promote their attack.

[0078] As described above, by combining nonspecific immunotherapy and specific immunotherapy, the effects of both can work synergistically, allowing cancer cells to be attacked by various immune functions. Therefore, a higher effectiveness can be expected compared to performing each therapy individually.

[0079] Figure 14 is a table that empirically rates the anticancer effects of each homogeneous dendritic cell vaccine manufactured according to the present invention. Rating A represents a major anticancer effect through direct attack on cancer cells. Rating B represents a lower anticancer effect than Rating A, as well as secondary effects such as suppression of cancer cell proliferation. Rating S represents an enhanced anticancer effect through direct attack on cancer cells by activated immune cells.

[0080] It should be noted that this rating of anti-cancer effect is based on experience and assumes that the expected effect is actually observed in patients. If the ligand for the specific immune dendritic cell vaccine does not match the patient's cancer cells, an anti-cancer effect may not be achieved; however, this case will not be considered. Furthermore, in the case of non-specific immune cell vaccines, the anti-cancer effect is exerted through various immune cells, but the degree of effectiveness varies depending on the characteristics of the patient's immune cells. In this case, the vaccines are ranked based on the average effect obtained empirically.

[0081] Figure 14 compares the combined efficacy ratings of non-specific immune cell vaccines and specific immune cell vaccines with the efficacy rating of the cocktail dendritic cell vaccine of the present invention. Since the anti-cancer effects of non-specific immune cell vaccines and specific immune cell vaccines overlap in terms of killer T cells, if we include the rating of one of them in the total, the effect of rating A will be 5 and the effect of rating B will be 5. In contrast, the anti-cancer effects of the cocktail dendritic cell vaccine are rated as follows: 6 for S-rated effects, 1 for A-rated effects, and 1 for B-rated effects. Empirically, this is higher than the combined effects of non-specific immune cell vaccines and specific immune cell vaccines. This is due to the enhancement of killer T cells and NK cells through adjuvant action, and the effective functioning of the anti-cancer effects of killer T cells through checkpoint inhibition. <Embodiment 1: Mainly corresponds to Claim 1 - Summary>

[0082] In this embodiment, monocytes are obtained from a patient by component blood collection, differentiated into immature dendritic cells, and then divided into multiple groups to generate different types of vaccines. By utilizing the immune activity that acts simultaneously through multiple routes, a method for producing a cocktail dendritic cell vaccine is provided that has a synergistic effect in attacking cancer cells compared to when each route acts individually. <Embodiment 1: Configuration mainly corresponding to Claim 1>

[0083] Embodiment 1 of the present invention is a method for producing a patient-specific cocktail dendritic cell vaccine, comprising: a preparation step of preparing to collect blood components from a patient; a blood component collection step of collecting a predetermined amount of monocytes from a patient ready for blood component collection in a single puncture (meaning that the collection of the predetermined amount of blood is completed in one cycle; multiple punctures are not prevented); a division step of dividing the monocytes or immature dendritic cells differentiated from monocytes collected only from the patient into multiple groups; a pulsing step of pulsing each group divided in the division step with a different type of ligand, optionally at different timings starting from the time of division; and a storage step of storing each group that has been pulsed with ligand. <Embodiment 1: Mainly corresponds to Claim 1 - Configuration Preparation Steps>

[0084] The "preparation step" is the step of preparing the patient for component blood collection. Blood sampling involves collecting monocytes, which are the precursors of dendritic cells. It is essential to ensure that a sufficient number of monocytes can be collected. Furthermore, it is necessary to check for any risks associated with existing diseases and to determine whether the patient is in a condition to withstand apheresis.

[0085] Monocytes are a type of white blood cell that, like other white blood cells, are produced in the bone marrow and make up 3-6% of white blood cells. When monocytes enter the body's tissues, they diversify into macrophages and dendritic cells. Therefore, a higher concentration of monocytes allows for the cultivation of more dendritic cells. <White blood cell count>

[0086] Therefore, a white blood cell count test is performed to confirm whether there is a sufficient white blood cell count, and if it does not meet the prescribed standard, medication is administered to raise the white blood cell count to the prescribed level. The white blood cell count should be at least 3000 / μl, preferably 4000 / μl or higher. <Managing bleeding risk>

[0087] In apheresis, blood is drawn from outside the body, its components are separated, and then the blood is returned to the body. This process is repeated. Therefore, an anticoagulant is mixed into the blood to prevent blood clotting in the apheresis machine. If the platelet count is lower than that of a healthy person, or if there are blood clotting disorders or bleeding from the affected area due to cancer, there is a possibility that the bleeding may not stop. For this reason, it is necessary to treat the area where bleeding is likely to occur and to ensure a sufficient platelet count. <Maintaining physical strength>

[0088] Since apheresis is a physically demanding procedure, it is necessary to ensure that the patient has the physical strength to withstand it. Patients with advanced-stage cancer are likely to have weakened physical strength, so adequate nutrition and hydration should be provided beforehand through intravenous fluids or other means. <Embodiment 1: Mainly corresponds to Claim 1. Configuration: Component blood collection step>

[0089] The "component blood collection step" is the step in which a predetermined amount of monocytes are collected from a patient who is ready for component blood collection in a single puncture (meaning the predetermined amount of blood collection is completed in one cycle; multiple punctures are not prohibited).

[0090] "Component aspiration" is the process of drawing blood from a patient's body (blood withdrawal), separating the desired components using a component aspiration machine, and returning the remaining blood to the body (blood return). This process is repeated until the desired amount of the desired component is collected. Therefore, a single puncture includes both the insertion of a needle connected to a tube for drawing blood and the insertion of a needle connected to a tube for returning blood to the body.

[0091] In the blood collection process for the cocktail dendritic cell vaccine of the present invention, monocytes are obtained. In a typical method, blood is collected by inserting a needle into the patient's left upper limb and also into the right upper limb, and the processed blood is returned. The collected blood is mixed with an anticoagulant such as sodium citrate, separated using a centrifuge, and separated into its various blood components. The layer containing monocytes is extracted and collected in a culture bag. The remaining components are mixed again and returned to the body. This process is repeated, and it takes about 3 hours to process the entire body's blood, which is approximately 4 liters. Therefore, the time required for apheresis varies depending on the amount of monocytes needed, but it generally takes at least 1 hour and 30 minutes.

[0092] In this component blood collection step, monocytes are separated as the target component, and approximately 100cc of blood (which may also contain plasma and platelets, etc.) with monocytes as the main component is collected. This blood component contains 200 x 10 7 It is preferable that the product contains one or more monocyte cells.

[0093] While separate tubes and needles for blood collection and blood return allow for faster collection, a single puncture can be used for both blood collection and return. In this case, blood collection, separation, and return are performed sequentially. Thus, the method of collecting monocytes from the patient's blood is not particularly limited.

[0094] Furthermore, if it becomes possible to generate monocytes from stem cells or iPS cells in the future, it is acceptable to culture them from stem cells or iPS cells obtained from patients using this method. In this invention, all methods are included as long as they allow for the acquisition of monocytes necessary for subsequent treatment in a single puncture, taking into account the patient's physical condition, etc. <Embodiment 1: Mainly corresponds to Claim 1. Configuration and division steps>

[0095] The "division step" is a step in which monocytes or immature dendritic cells differentiated from monocytes, collected from the patient's own blood, are divided into multiple groups. Immature dendritic cells differentiated from monocytes are divided into separate culture containers (e.g., petri dishes, beakers, graduated cylinders, etc.) in a predetermined ratio. This ratio is determined based on the ratio in which the dendritic cell vaccine pulsed with a specific ligand will ultimately be produced. Based on this ratio, the ligand is pulsed in the pulse step described later, but at least one of the culture containers containing these divided immature dendritic cells will be pulsed with the NKT-activating ligand, and this ratio should be 3% or more of the total, and not exceed 30%. In the case of division at the monocyte stage, the cells may first be divided equally, allowed to mature into immature dendritic cells under the same conditions for a certain period of time, and then combined again and divided again. This has the effect of homogenizing the multiple divided immature dendritic cells. One advantage of dividing cells at the monocyte stage is that, in the event of contamination, the contaminated divided cells become unusable, but the remaining divided cells can be utilized. In addition, the conditions for maturing monocytes into immature dendritic cells may vary slightly depending on the patient's immune system, and it is possible to create good quality immature dendritic cells by trial and error with multiple conditions.

[0096] This is because NKT cells are said to make up only about 0.1% of T cells in peripheral blood, making them extremely rare. Therefore, vaccines that target NKT cell activation, which constitute nonspecific immunotherapy, may be ineffective even when administered in large quantities. In other words, dendritic cell vaccines pulsed with NKT-activating ligands tend to plateau in effectiveness with increasing dosage. Consequently, it is preferable to allocate more resources to specific immunotherapy.

[0097] Furthermore, the division in the "division step" can also be performed by dividing the cells while they are still monocytes and allowing them to differentiate into immature dendritic cells. It is preferable to divide the cells into containers that can be used for direct culture, such as petri dishes. The division ratio at this time is the same as when dividing the cells while they are still immature dendritic cells. However, it is preferable to perform the division at the immature dendritic cell stage. This is because it helps to minimize variations in the quality of cells included in the multiple groups being divided. This is because cells tend to mature at varying rates within their culture vessels, and if division is performed at the early monocyte stage, the effect of the ligand pulse may vary. <Embodiment 1: Mainly corresponds to Claim 1. Configuration: Dividing step, First culture substep>

[0098] The division step includes the "first culture substep." The first culture substep involves culturing monocytes collected from the patient's own blood in an incubator for 5 to 7 days to differentiate them into immature dendritic cells. By placing monocytes in a culture medium (serum-free medium optimized for dendritic cells), adding stimulating cytokines (e.g., interleukins such as IL4, GM-CSF, etc.), and culturing, differentiation into immature dendritic cells is induced. A characteristic of live immature dendritic cells is that after 2 days of culture, downstream regulation of CD14 surface expression, increased dextran reuptake, and increased response to MIP-1a can be detected, and the differentiation of immature dendritic cells can be observed using these as indicators. Regarding the culture method here, various studies and proposals have been made to improve efficiency and stability, so any method should be used. Any method is acceptable as long as immature dendritic cells can be efficiently and stably generated from monocytes. It is preferable to perform the first culture step in a single culture vessel to avoid variations in culture. However, when dividing monocytes and culturing them after division, each group should be cultured separately. It is also possible to vary the culture conditions for the divided monocytes to control the quality of immature dendritic cells. Culture conditions can also be determined according to the type of ligand to ensure that the ligand applied later is effective. The effectiveness of the ligand must be determined by comprehensively considering factors such as antigen presentation ability, maturation rate, and the control of the properties of immature dendritic cells present when reintroduced into the patient's body. Culture conditions include temperature, type of culture medium, nutrients supplied, and time. <Embodiment 1: Mainly corresponds to Claim 1. Configuration: Pulse step>

[0099] The "pulse step" is a step in which different types of ligands are pulsed to each group separated in the splitting step, sometimes at different timings starting from the splitting time. A "ligand" refers to a substance that forms a complex with a biomolecule and protein to achieve a biological purpose. In this context, it refers to a substance that specifically binds to various receptors on immune cell membranes, thereby activating the immune system. Ligands are composed of amino acids, peptides, proteins, glycolipids, and other similar substances. In this context, "pulsing" refers to the process of adding an antigen-containing drug to the culture target to accelerate the culture. Specifically, it involves adding a ligand, such as a peptide or α-galactosylceramide, to immature dendritic cells, culturing them, and generating mature dendritic cells. Note that the rate at which immature dendritic cells mature may differ depending on the type of ligand used for pulsing. Therefore, it becomes necessary to pulse at different timings, starting from the cell division stage. This is because the initiation of specific immunotherapy and non-specific immunotherapy needs to be approximately the same time in order to expect synergistic effects from both. Furthermore, it is preferable to minimize the storage period (freezing period) in order to minimize the amount of highly active mature dendritic cells or dysfunctional mature dendritic cells.

[0100] Here, there are two types of pulsing ligands, one of which is NKT cell ligand, which is classified as nonspecific immunotherapy and is also called NKT cell targeted therapy. The other type is classified as specific immunotherapy, which uses cancer antigens as ligands.

[0101] An "NKT cell activating ligand" is a glycolipid that activates NKT cells. NKT cells are activated when NKT cell-activating ligands are presented by antigen-presenting cells such as dendritic cells. Activated NKT cells produce large amounts of interferon (IFN-γ), which can activate various immune cells. Furthermore, since NKT cells do not specifically target cancer cells, and the receptors for NKT cells are common and not subject to individual differences, a certain level of effectiveness can be expected for everyone. In recent years, α-galactosylceramide has attracted attention as an NKT cell-activating ligand, but ligands with even greater efficacy than α-galactosylceramide are also being researched and developed. Therefore, if new NKT cell-activating ligands are developed in the future, they may be used.

[0102] Cancer antigens are proteins (including peptides) with unique structures found in cancer cells, structures not present in normal cells. When antigen-presenting cells such as dendritic cells present them as antigens to T cells, the T cells are activated, and they recognize the cancer cells as targets for attack using the protein structure of the cancer antigen as a marker. Therefore, if the amino acid structure of the artificial cancer antigen presented by dendritic cells matches the amino acid structure of the cancer cells affecting the patient, it will be effective, but if they do not match, it will not be effective. In this context, a cancer antigen called WT1 peptide has shown relatively high efficacy in recent years.

[0103] The "WT1 peptide" is an artificial cancer antigen with a protein structure common to various cancers. Therefore, it can be used for most cancer patients and a certain level of effectiveness can be expected. For this reason, using the WT1 peptide as a ligand is highly efficient, except in cases of rare cancers.

[0104] Furthermore, while numerous artificial cancer antigens exist, not limited to WT1, there is also a method of artificially generating antigens by culturing or identifying proteins extracted from the patient's own cancer cells or tissues. In this case, because it is based on the patient's own cancer cells or similar substances, the amino acid structure of the antigen matches, and a higher efficacy can be expected. Such ligands, known as neoantigens, are also being put into practical use.

[0105] "Neoantigens," also known as newly formed antigens, are proteins expressed in cells that have undergone genetic changes not present in normal cells. These proteins are artificially identified and produced. To perform this identification, it is necessary to analyze new cancer tissue, which is the precursor to genetic changes, and neoantigens can primarily be extracted from blood. Neoantigens vary from patient to patient and can also change depending on the stage of cancer progression. Therefore, it is most effective to use neoantigens that have been identified as recently as possible.

[0106] Thus, research into cancer antigens that can be used as ligands is progressing daily, and any ligand belonging to specific immunotherapy, even newly discovered ones, can be used as ligands in the method for producing the cocktail dendritic cell vaccine of the present invention.

[0107] As described above, various ligands can be used in the pulse step, but in the division step, at least one group of immature dendritic cells should be treated with a ligand corresponding to nonspecific immunotherapy, and the remaining group should be treated with a ligand corresponding to specific immunotherapy. In other words, immature dendritic cells are used in the division step so that they contain both ligands corresponding to nonspecific immunotherapy and ligands corresponding to specific immunotherapy. <Embodiment 1: Mainly corresponds to Claim 1. Configuration: Pulse step, Second culture substep>

[0108] The pulse step includes a second culture substep in which immature dendritic cells are matured into mature dendritic cells by pulsing them with a ligand during culture. Once the immature dendritic cells take up the added ligand as an antigen, they mature by being cultured for about 1 to 3 days. The proportion of mature dendritic cells after culture should be 70% or more, preferably 80% or more, but the schedule may be arranged so that some immature dendritic cells remain. These immature dendritic cells can be used to strengthen the immune system that was not fully prepared in the diagnostic or treatment plan by acting as an immune system adapted to the patient's condition after being returned to the body. <Embodiment 1: Mainly corresponds to Claim 1 - Configuration - Storage Step>

[0109] The "storage step" is the step of storing each group of ligands that have been pulsed. In the pulse step, the dendritic cells mature into mature dendritic cells, and the resulting liquid, which is then injected into storage containers such as vials for each group, and stored. In other words, storage containers are created that contain the dendritic cell vaccine for the number of doses administered to the patient, or even more. This should be stored frozen at -80°C or below until administration, but it is not limited to frozen storage; if the vaccine is suitable for refrigeration, it may be stored in the refrigerator. Also, if the dendritic cell vaccine is to be administered to the patient immediately after production, there is no restriction on storing it in the refrigerator or at room temperature. The storage step does not necessarily have to be performed on all divided groups; it may be configured to be performed only on some of the groups. Alternatively, the divided and matured groups of dendritic cells may be reintegrated and stored in a mixed state containing multiple types of mature dendritic cells. In particular, if the storage step is performed using low-temperature freezing, it may be advisable to integrate the entire group before storage to prevent minute variations in the quality degradation of mature dendritic cells during storage from occurring among multiple groups of mature dendritic cells. <Embodiment 1: Mainly corresponds to Claim 1. Configuration: Storage step, Storage container division substep>

[0110] The storage step may include a "container division substep." The medication should be divided into smaller doses than a single dose administered to a patient, and stored in vials or other storage containers. The reason for limiting the dosage to less than one dose is that the optimal dose of dendritic cell vaccine varies from patient to patient. For example, one patient may require 1 x 10 6 An effect was observed even with a dose equivalent to the number of individual cells, but in one patient, 1 × 10⁶ 7 In some cases, the vaccine may not be effective unless administered in an amount equivalent to the number of individual cells. Also, since it is single-use after thawing, any remaining vaccine would be wasted. For these reasons, one storage container should hold the minimum expected amount, and only the number of storage containers needed to secure a single dose should be thawed and used. As described above, the method for producing the cocktail dendritic cell vaccine of the present invention generates multiple dendritic cell vaccines. <Embodiment 1: Mainly corresponds to Claim 1. Flow Description>

[0111] Figure 3 is a flowchart showing the method for producing the cocktail dendritic cell vaccine of the present invention. The details of each step are the same as those described in the structure section; this flowchart provides a general overview. First, in preparation step 0301, preparations are made to allow for apheresis collection from the patient to be treated. Specifically, the white blood cell count is tested, and if it is lower than the specified value, a drug to increase the white blood cell count is administered and the patient's condition is monitored. In addition, nutritional supplements and hydration are provided to ensure the patient is in a healthy condition suitable for apheresis collection. Next, in step 0302, apheresis is performed. The component collected in apheresis is monocytes, and approximately 100cc of blood, mainly composed of monocytes, is collected. Next, in division step 0303, immature dendritic cells differentiated from monocytes collected from the patient are divided into multiple groups in a predetermined ratio. Differentiation from monocytes to immature dendritic cells is carried out by placing monocytes in a culture medium, adding cytokines (stimulating factors), and culturing them for about 5 days. Next, in ligand pulse step 0304, a different ligand is added to each group of immature dendritic cells in a culture medium that has been divided into multiple groups, and the cells are cultured. Here, the immature dendritic cells take up the ligand and mature into mature dendritic cells over a period of 2 to 3 days. Finally, in storage step 0305, the mature dendritic cells, which were cultured in multiple groups, are divided into single-dose portions, transferred to storage containers, and stored frozen at -80°C or below. The above describes the manufacturing process for the cocktail dendritic cell vaccine of the present invention. <Embodiment 1: Mainly corresponds to Claim 1; Effects>

[0112] A cocktail dendritic cell vaccine, consisting of multiple dendritic cell vaccines including a nonspecific immune dendritic cell vaccine and a specific immune dendritic cell vaccine, can be produced from a single blood sample. Culturing from a single blood sample ensures the homogeneity of the dendritic cells in the multiple dendritic cell vaccines, resulting in a reliable synergistic effect. Homogeneity is further enhanced when creating a cocktail dendritic cell vaccine by dividing the extracted monocytes into multiple groups after they have grown to a certain extent and then pulsing them with different ligands. This is because cell growth rates vary greatly in the early stages, and this variation gradually decreases as growth progresses. Furthermore, since apheresis is burdensome for patients and cannot be performed repeatedly in a short period, generating multiple dendritic cell vaccines from a single blood sample ensures simultaneous administration without wasting time. Therefore, patients can achieve a high anti-cancer effect through the synergistic effect of improved immunity and enhanced anti-cancer action. <Embodiment 2: Primarily corresponds to Claim 2 - Summary>

[0113] In Embodiment 2, in addition to the procedure of Embodiment 1, the patient's immune status and disease-related information are obtained before the preparation step, and the optimal ligand is selected according to the patient's condition. <Embodiment 2: Configuration mainly corresponding to claim 2>

[0114] Embodiment 2, in addition to the procedure of Embodiment 1, includes an immunity / disease information acquisition step before the preparation step in which one or more of the following are acquired: immunity information, which is information about the patient's immune system; the patient's individual biological information; and the patient's disease information. The ligand to be pulsed in the pulse step is selected according to the acquired immunity / disease information.Details of each component will be described, with the explanation of components that overlap with Embodiment 1 being omitted, and only the added steps being explained. <Embodiment 2: Primarily corresponds to Claim 2. Configuration: Step for acquiring immunity and disease information>

[0115] The "Immunity and Disease Information Acquisition Step" is a step performed before the preparation step to acquire one or more of the following: information about the patient's immunity, the patient's personal biological information, or the patient's disease information. "Immune system and disease information" refers to information related to a patient's immune system, and includes immune system information obtained from blood tests, etc., as well as disease information obtained from various tests such as blood tests, tumor markers, cancer tissue biopsies, X-rays, CT scans, and MRIs, which also include information related to cancer and its associated complications, as well as other diseases.

[0116] Blood tests can examine conditions such as white blood cell count, immunoglobulin levels, presence or absence of immunodeficiency, complement levels, and presence or absence of autoimmune diseases. White blood cell count, which measures the proportion of lymphocytes and monocytes, is an important item in the manufacturing of this immunoactivated vaccine. Immunoglobulins include IgG, IgA, and IgM, and abnormal values ​​may suggest diseases other than cancer, so prior treatment may be considered. Immunodeficiency is checked by testing for HIV1 and HIV2 antibodies, and if there are problems, it means that T cells and B cells, which are responsible for major immune functions, are not functioning properly, so treatment to improve the immunodeficiency is necessary. Tumor markers are tests that examine the levels of characteristic proteins and other substances produced by different types of cancer. Representative examples include CEA, AFP, BCA225, BFP, CA15-3, and CA19-9, which can indicate whether cancer metastasis is suspected. If the type of cancer is known, the appropriate ligand can be selected for pulsation. Alternatively, the ligand to be pulsed can be customized according to the patient's cancer site. Biopsies of cancerous tissue also involve ligand selection. X-rays, CT scans, and MRIs are used to visually confirm the progression of the original cancerous disease and to identify areas where metastasis is suspected using tumor markers.

[0117] By using such information related to immunity and disease, it is conceivable that it could be used, for example, as an indicator for selecting the ligand to be used, or for determining the administration plan regarding the administration interval and duration of this cocktail dendritic cell vaccine.

[0118] The step of acquiring immunity and disease information may also be performed after administration of the dendritic cell vaccine produced by the cocktail dendritic cell vaccine production method of the present invention. For example, this may involve confirming the induction status of killer T cells or confirming an increase in IFN-γ levels. When a specific immune dendritic cell vaccine is administered, the induction of killer T cells can be confirmed as an indicator of effectiveness. When a non-specific immune dendritic cell vaccine is administered, the degree of effectiveness can be evaluated by examining the increase in IFN-γ levels. For example, if there are three or more divided groups, after administering the first two dendritic cell vaccines to the patient's body, immature dendritic cells set aside as reserves may be pulsed with a new ligand based on the evaluation results to mature them and generate additional new dendritic cell vaccines.

[0119] On the other hand, the amount of dendritic cell vaccine needed to be effective varies from patient to patient. Specifically, with specific immune dendritic cell vaccines, the induction of killer T cells varies from patient to patient. Also, with non-specific immune dendritic cell vaccines, once IFN-γ levels reach a predetermined level, further administration is not necessary until the effect diminishes. Given these circumstances, it is conceivable to determine the production quantity of the dendritic cell vaccine while monitoring the patient's immune response after administering the dendritic cell vaccine produced by the cocktail dendritic cell vaccine production method of the present invention. <Embodiment 2: Mainly corresponds to Claim 2. Configuration: Ligand Selection Step>

[0120] The "ligand selection step" is a step in which the ligand to be pulsed in the pulse step is selected according to the acquired immunity and disease information. First, in specific immunotherapy, cancer antigens are used as ligands, but there are also many artificially generated cancer antigens. Table 1 below lists some representative artificial cancer antigens. [Table 1] Thus, there are many cancer antigens that can be used as ligands, depending on the location of the cancer, and it is necessary to determine which ligand is effective for the patient based on the patient's test results (location of the cancer, stage of cancer progression, tumor marker levels, etc.).

[0121] Alpha-galactosylceramide is a well-known ligand used in nonspecific immunotherapy. Research is also underway to find ligands that are more effective than alpha-galactosylceramide. If an effective ligand is discovered in the future, and it is a ligand that activates NKT cells, it will be included as a ligand that can be used in this cocktail dendritic cell vaccine. <Embodiment 2: Mainly corresponding to Claim 2 - Flowchart Description>

[0122] Figure 4 is a flowchart showing the procedure of Embodiment 2. Steps that overlap with Embodiment 1 will not be explained, and only the different steps will be described. First, in the immunity and disease information acquisition step 0406, necessary tests (e.g., blood tests, tumor markers, CT scans, MRI, etc.) are performed according to the patient's condition to acquire immunity and disease-related information about the patient's immune system. Subsequently, the preparation step 0401, the component blood collection step 0402, and the division step 0403 are performed in the same manner as in Embodiment 1. In parallel with this, prior to pulse step 0404, the optimal ligand is selected in ligand selection step 0407 based on immune system and disease information. For example, one possible approach is to select an artificial ligand that is appropriate for the location of the patient's cancer. Subsequently, the pulse step 0404 and storage step 0405 are performed in the same manner as in Embodiment 1, but the ligand used for pulsing in pulse step 0404 is the one selected in ligand selection step 0407. The above describes the method for producing the cocktail dendritic cell vaccine according to Embodiment 2. <Embodiment 2: Mainly corresponds to Claim 2; Effects>

[0123] As described above, the cocktail dendritic cell vaccine of Embodiment 2 allows for the selection of the optimal ligand depending on the site and type of cancer, resulting in a higher anti-cancer effect. Furthermore, in cases of diseases other than cancer, such as viral or bacterial infections, the antigen of the virus or bacteria can be used as a ligand in a portion of the divided immature dendritic cells. This makes it possible to manufacture a cocktail dendritic cell vaccine that can treat multiple diseases simultaneously. <Embodiment 3: Primarily corresponds to Claim 3 - Summary>

[0124] Embodiment 3, in addition to Embodiment 2, determines the ratio of immature dendritic cells to be divided in the division step based on the immune system and disease information obtained in the immune system and disease information acquisition step. <Embodiment 3: Configuration mainly corresponding to claim 3>

[0125] Embodiment 3, in addition to the configuration of Embodiment 2, further includes a division ratio determination step that determines the division ratio when dividing in the division step according to the acquired immunity and disease information, thereby producing a cocktail dendritic cell vaccine. Details of each component will be described, with the explanation of components that overlap with Embodiment 2 being omitted, and only the added steps being explained. <Embodiment 3: Mainly corresponds to Claim 3 - Configuration - Step for determining the division ratio>

[0126] The "division ratio determination step" is the step in which the division ratio of immature dendritic cells in the division step is determined. The present invention provides a method for producing a cocktail dendritic cell vaccine, comprising a dendritic cell vaccine using a ligand corresponding to specific immunotherapy and a dendritic cell vaccine using an NKT cell activating ligand corresponding to nonspecific immunotherapy. Furthermore, depending on factors such as the type and stage of the patient's cancer, and whether artificial or patient-derived cancer peptides are used, multiple ligands may be used as ligands for specific immunotherapy. Additionally, if the patient has other diseases treatable with dendritic cell vaccines, ligands corresponding to those conditions may be used. This step involves determining the ratio in which the immature dendritic cells pulsed with these ligands will be divided. This division ratio represents the ratio in which immature dendritic cells are divided, and this ratio corresponds to the proportion of dendritic cells contained in the dendritic cell vaccine produced by the cocktail dendritic cell vaccine production method of the present invention. Therefore, this ratio may significantly affect the therapeutic effect on patients who are administered the dendritic cell vaccine produced by the cocktail dendritic cell vaccine production method of the present invention.

[0127] For example, if the information obtained in the immunity / disease information acquisition step indicates that the patient's immunity is high, then it might be possible to use a lower concentration of nonspecific immune dendritic cell vaccine, for example, 3-6%, and a higher concentration of specific immune dendritic cell vaccine, for example, 94-97%.

[0128] Furthermore, if the patient's immune system shows low levels, and the cancerous area has been surgically removed or the cancer is still in its early stages, it may be advisable to reduce the proportion of specific immune dendritic cell vaccines and use a 30% non-specific immune dendritic cell vaccine to allow for long-term administration. While the above describes extreme cases, it is desirable to manufacture each dendritic cell vaccine in the optimal ratio, taking into account the individual patient's immune system and disease information. Note that the division ratio here affects the number of dendritic cells, but does not correspond to the amount of vaccine administered per dose. In other words, the number of dendritic cells per unit volume contained in the solution of a non-specific immune dendritic cell vaccine and a specific immune dendritic cell vaccine may differ. This is because the amount of ligand that can pulse dendritic cells differs depending on the ligand.

[0129] Figure 11 shows an example of a table for determining the ratios in the division step. This ratio represents the division ratio of immature dendritic cells and does not correspond to the amount of dendritic cell vaccine produced. The row represents an evaluation value of immunity, which is divided into three levels: "Normal" represents the average level of immunity for a healthy person, "Weak" indicates a lower level of immunity than average, and "Strong" indicates a state where immunity is more active than normal. One possible method for evaluating immune function is to obtain interferon levels and evaluate them on a three-point scale. To give a specific example, in cases of low immunity, where immunity needs to be strengthened, the amount of non-specific immune dendritic cell vaccine is increased to no more than 20%, and the remainder is produced using specific immune dendritic cell vaccine. Conversely, in cases where the immunity assessment value is strong and relatively high, the focus is on specific immunotherapy, and the amount of non-specific immune dendritic cell vaccine is reduced to around 5%, with the remainder being produced using specific immune dendritic cell vaccine. <Embodiment 3: Mainly corresponding to Claim 3 - Flowchart Description>

[0130] Figure 5 is a flowchart showing the procedure of Embodiment 3. Steps that overlap with other embodiments will not be explained, and only the different steps will be described. The division ratio determination step 0508 determines, at the latest before the division step 0503, the number of divisions and the division ratio for dividing immature dendritic cells in the division step 0503, based on the immune system and disease information obtained in the immune system and disease information acquisition step 0506. In the division step 0503, the immature dendritic cells are divided into multiple groups based on the number of divisions and division ratio determined in the division ratio determination step. <Embodiment 3: Mainly corresponds to Claim 3; Effects>

[0131] By assessing the patient's condition through examinations and determining the optimal dendritic cell vaccine production ratio for that patient, it becomes possible to manufacture a more effective cocktail dendritic cell vaccine with higher anti-cancer efficacy. <Embodiment 4: Mainly corresponds to Claim 4 - Summary>

[0132] Embodiment 4 creates an administration plan for the dendritic cell vaccine produced by the cocktail dendritic cell vaccine production method of the present invention to patients based on the immunity and disease information obtained in the immunity and disease information acquisition step, and determines the storage period for each storage container stored in the storage step. <Embodiment 4: Configuration mainly corresponding to claim 4>

[0133] Embodiment 4, in addition to Embodiment 2 and the embodiments including Embodiment 2, further comprises a storage period determination step in which the storage period for each group in the storage step is determined according to the acquired immunity and disease information, thereby producing a cocktail dendritic cell vaccine. <Embodiment 4: Mainly corresponding to Claim 4 - Configuration - Storage Period Determination Step>

[0134] The "storage period determination step" determines the storage period for each storage container of dendritic cell vaccine, which is divided into individual storage containers and frozen for storage, based on the immunity and disease information obtained in the immunity and disease information acquisition step. For example, nonspecific immune dendritic cell vaccines are administered at intervals of 2 to 8 weeks. However, for patients judged to have weakened immunity based on their immune status and disease information, the vaccine is administered at shorter intervals, closer to 2 weeks. For patients judged to have no weakened immunity, the vaccine is administered at intervals closer to 8 weeks, so that the duration of one treatment cycle is longer. Specific immune dendritic cell vaccines are administered at intervals of 2 to 4 weeks. However, for patients whose cancer is judged to be rapidly progressing based on their immune status and disease information, the administration interval should be shorter, closer to 2 weeks, and the dosage should be set higher. For patients whose cancer is not rapidly progressing, such as those who have undergone surgical removal of the cancerous area, administration may be at intervals closer to 4 weeks, or the dosage may be gradually increased from a small amount to determine the appropriate dose.

[0135] As described above, based on the immunity and disease information obtained in the immunity and disease information acquisition step, an administration plan is created for the dendritic cell vaccine produced by the cocktail dendritic cell vaccine production method of the present invention, including the administration interval, administration period, and dosage. Based on the created administration plan, in the storage step, the dendritic cell vaccine is stored in storage containers in a dose equal to or less than one dose. The number of divisions to be divided into storage containers, the amount of dendritic cell vaccine to be stored in each storage container, and the storage period for each storage container are determined.

[0136] Figures 12 and 13 show an example of how the storage period for each storage container of the dendritic cell vaccine was determined based on the administration plan. The black triangles indicate the timing of administration, and the lines indicate the storage period, with each square representing two weeks. Figure 12 shows the administration plan created for patients with a weak immune response in Figure 11. As shown in the figure, the storage period for each storage container is determined so that the specific immune dendritic cell vaccine can be administered every two weeks. The storage period for the non-specific immune dendritic cell vaccine is determined so that it can be administered only twice, at the beginning and end of the treatment period, with one course of treatment planned to last three months. Figure 13 shows a case where the vaccine is administered to prevent metastasis and recurrence after surgical treatment for cancer, for example. In this case, the severity of cancer symptoms is relatively low, and the treatment plan is to treat the patient gradually over the long term. As shown in the figure, the specific immune dendritic cell vaccine is initially administered every three weeks, and then every four weeks thereafter. The non-specific immune dendritic cell vaccine is scheduled to be administered approximately every 12 weeks. Furthermore, it is preferable to administer nonspecific immune dendritic cell vaccines in one to three doses during a single course of treatment, regardless of the amount divided at each stage of the division process. <Embodiment 4: Mainly corresponding to Claim 4 - Flowchart Description>

[0137] Figure 6 is a flowchart showing the procedure of Embodiment 4. Steps that overlap with other embodiments will not be described, and only the different steps will be described. The storage period determination step involves creating a treatment plan for the dendritic cell cocktail vaccine for the patient based on the immunity and disease information obtained in the immunity and disease information acquisition step. Based on this information, the storage period for each storage container containing the dendritic cell vaccine, which was divided into individual doses and stored in storage containers during the storage step, is determined. <Embodiment 4: Mainly corresponds to Claim 4; Effects>

[0138] Based on an administration plan appropriate to the patient's condition, the storage period for each storage container is determined based on the administration plan, which includes the number and amount of divisions of the dendritic cell vaccine produced by the present invention's method for producing the cocktail dendritic cell vaccine into storage containers, the administration interval, and the administration period. This allows the cocktail dendritic cell vaccine to be used effectively according to the patient's condition and to be kept in a stable state until administration. <Embodiment 5: Mainly corresponds to claim 5 - Summary>

[0139] Embodiment 5 involves observing a dendritic cell vaccine composed of mature dendritic cells cultured by pulsing a ligand in a pulse step to confirm the viability of the dendritic cells and the presence of foreign substances, thereby confirming that the vaccine is of a quality that is safe to administer to patients. <Embodiment 5: Configuration mainly corresponding to claim 5>

[0140] Embodiment 5 is a method for producing a cocktail dendritic cell vaccine that, in addition to the configuration of any one of Embodiments 1 to 4, further comprises an observation result acquisition step in which each group pulsed with ligand after the pulse step is observed and observation results are obtained. <Embodiment 5: Mainly corresponds to Claim 5. Configuration: Observation result acquisition step>

[0141] The "observation results acquisition step" involves observing the mature dendritic cells obtained through the pulse step under magnification using a microscope or other means to confirm whether the dendritic cell vaccines of each group have been produced to the specified quality, including the maturation rate, viability rate, and whether there is any contamination due to foreign substances.

[0142] The maturation rate of dendritic cells refers to the time it takes for dendritic cells to take up ligands and mature, which usually requires a culture period of 2 to 3 days. Dendritic cells only acquire antigen-presenting ability when they are mature, so if maturation is insufficient, the desired effect cannot be obtained. Therefore, if the maturation rate is judged to be low, it is desirable to increase the maturation rate by extending the culture period.

[0143] The survival rate is affected by the death of cells during the differentiation process from monocytes to immature dendritic cells and then to mature dendritic cells. Additionally, some cells die due to their natural lifespan after maturation. If a large number of cells die, the effectiveness may decrease, requiring adjustments such as increasing the dosage.

[0144] Contamination due to foreign matter refers to checking whether fungi introduced during the production of this cocktail dendritic cell vaccine, or bacteria originally present in the blood, have proliferated through culture. If contamination due to fungal or bacterial growth is detected, it is dangerous to administer the vaccine to patients, and production of this cocktail dendritic cell vaccine must be stopped and the preparation steps restarted.

[0145] Furthermore, the number of mature dendritic cells per unit area is counted to estimate the total number of mature dendritic cells. This allows us to determine how many doses of the dendritic cell vaccine have been secured. <Embodiment 5: Mainly corresponding to claim 5 - Flowchart description>

[0146] Figure 7 is a flowchart showing the procedure of Embodiment 5. Steps that overlap with other embodiments will not be described, and only the different steps will be described. In observation result acquisition step 0710, the condition of the dendritic cell vaccine cultured in multiple groups in pulse step 0704 is observed using a microscope or other means to obtain information related to the quality of the dendritic cell vaccine, such as the maturity of the dendritic cells, the viability of the dendritic cells, the number of dendritic cells, and whether or not there is contamination due to foreign matter. If there are no problems with the dendritic cell vaccine in each group, the process proceeds to storage step 0705, where the vaccine is stored until administration. <Embodiment 5: Mainly corresponds to claim 5. Effects>

[0147] By checking the condition of the dendritic cells within the dendritic cell vaccine and ensuring it is free from foreign contamination, the quality of the cocktail dendritic cell vaccine can be guaranteed, and medical issues can be prevented in advance. Furthermore, by checking the activity level and number of dendritic cells, it is possible to create an administration plan and estimate the effects after administration in advance. <Embodiment 6: Mainly corresponds to claim 6 - Summary>

[0148] Embodiment 6 creates an administration plan for the cocktail dendritic cell vaccine based on the observation results obtained in the observation results acquisition step, and determines the storage period in the storage step. The effectiveness of dendritic cell vaccines varies depending on the number, activity, and maturity of the dendritic cells, but the quantity and quality of dendritic cells obtained through culture largely depend on the characteristics of the patient's monocytes. Therefore, a key feature of this embodiment is that, based on the actual culture results, a dosing plan is created in the storage step, determining the number of divisions to be placed in storage containers and the amount of dendritic cell vaccine to be stored in each container before storage. <Embodiment 6: Configuration mainly corresponding to claim 6>

[0149] Embodiment 6 has the same configuration as Embodiment 5, but the effect of the storage step is different. <Embodiment 6: Mainly corresponds to claim 6 - Configuration - Storage step>

[0150] In the storage step of this embodiment, the single dose, number of doses, etc. are determined based on the observation results obtained in the observation result acquisition step, such as the number of mature dendritic cells and the activity level of the dendritic cells, and the number of divisions to be made in the aforementioned storage container division step is determined. Furthermore, in the storage period determination step, the single dose and number of administrations may be determined based on the administration interval and duration, which are determined based on the patient's immune system and disease information. <Embodiment 6: Mainly corresponding to claim 6 - Processing flow> The processing flow of Embodiment 6 is the same as that of Embodiment 5, but the effect of the storage step is different. The details of the effect of the storage step have been explained in the configuration section and will be omitted here. <Embodiment 6: Mainly corresponds to claim 6. Effects>

[0151] The quality of each dendritic cell vaccine is observed to determine the dosage and number of doses, allowing for the division and storage of the dendritic cell vaccine to ensure effectiveness according to the quality of the immune-activating vaccine. <Embodiment 7: Mainly corresponds to claim 7 - Summary>

[0152] Embodiment 7 involves cryopreserving at least one of the multiple groups of immature dendritic cells divided in the division step, and performing the subsequent pulse step and storage step at a different time than the other groups. <Embodiment 7: Configuration mainly corresponding to claim 7>

[0153] Embodiment 7, in addition to the configuration of any one of Embodiments 1 to 6, further comprises a freezing / refrigeration storage step in which at least one of the groups divided between the division step and the pulping step is frozen or refrigerated for the production of a cocktail dendritic cell vaccine. <Embodiment 7: Mainly corresponds to claim 7. Configuration: Freezing / refrigeration storage step>

[0154] The "freezing / refrigeration step" involves freezing a portion of the immature dendritic cells, which have been divided into multiple groups. This allows for storage for approximately one to three months. After this, the ligand to be used in the pulse step is determined, and the pulse step and storage step are performed to create one or more dendritic cell vaccines that make up the cocktail dendritic cell vaccine. Of course, this does not prevent storage for more than three months.

[0155] This storage period is, for example, to allow time to identify and produce the composition of proteins (including peptides) to be used as ligands from patient-derived tissues such as neoantigens. Patient-derived tissue refers to the patient's own cells, and it takes a lot of time to produce it because it involves searching for gene mutations that are beginning to transform into cancer cells and identifying their composition. Therefore, until these patient-derived ligands are produced, dendritic cell vaccines using existing ligands are produced and administered using immature dendritic cells that were not stored in the freezing / refrigeration step. Once patient-derived ligands are produced, dendritic cell vaccines using these ligands are produced and the administration switches to these.

[0156] Furthermore, the effectiveness of a dendritic cell vaccine using a specific ligand for a patient cannot be determined until it is actually administered. This is because the compatibility between the patient's cancer and the antigen used as the ligand is also a factor, and if the effect is low, it may be more effective to switch to a different ligand. For these reasons, a dendritic cell vaccine produced from immature dendritic cells that were not stored in the frozen / refrigerated storage step should be administered to confirm its effectiveness before determining the ligand to be used for immature dendritic cells that were stored in the frozen / refrigerated storage step. To determine if it is effective, after administering the dendritic cell vaccine to the patient, an immunity / disease information acquisition step should be performed to obtain immunity / disease information, and based on that immunity / disease information, a ligand should be selected in the ligand selection step. <Embodiment 7: Mainly corresponding to claim 7 - Processing flow>

[0157] Figure 8 is a flowchart showing the procedure of Embodiment 7. Steps that overlap with other embodiments will not be described, and only the different steps will be described. Step 0811 involves freezing or refrigerating at least one of the groups of cells that were differentiated into immature dendritic cells in step 0803 and divided into multiple groups. The remaining groups proceed directly to step 0804 and storage step 0805. The groups stored in the freezing / refrigeration step undergo the ligand step and storage step at a later and different timing than the other groups. <Embodiment 7: Mainly corresponds to claim 7. Effects>

[0158] By storing the immature dendritic cells divided in the division step by freezing or refrigeration, treatment can proceed with a portion of the dendritic cell vaccine produced using existing ligands in the cocktail dendritic cell vaccine production method of the present invention, while simultaneously identifying and generating cancer antigens derived from the patient's biological tissue. Once these antigens are produced, the dendritic cell vaccine can be generated using the frozen, stored immature dendritic cells. This allows for the production of a dendritic cell vaccine with higher anti-cancer efficacy.

[0159] Furthermore, it is impossible to know whether a ligand is sufficiently effective for a patient until after administration. If the dendritic cell vaccine produced in the previous group does not show sufficient efficacy, a dendritic cell vaccine is produced using a different ligand. Whether or not it was effective can be determined by examining the rate of killer T cell induction. If sufficient efficacy is observed, the same ligand as the previously produced dendritic cell vaccine can be used. This increases the likelihood of achieving a higher anti-cancer effect. <Embodiment 8: Mainly corresponds to claim 8 - Summary>

[0160] Embodiment 8 generates cancer antigens based on the patient's individual biological tissue and uses them as ligands. <Embodiment 8: Configuration mainly corresponding to claim 8>

[0161] Embodiment 8, in addition to the configuration of any one of Embodiments 1 to 7, further comprises a ligand generation step that generates ligands based on the patient's individual body tissue, and a pulse step configured to pulse the ligands generated in the ligand generation step to produce a cocktail dendritic cell vaccine. <Embodiment 8: Mainly corresponds to claim 8. Configuration: Ligand generation step>

[0162] The "ligand generation step" is the step of generating cancer antigens to be used as ligands from patient-derived tissue. Patient-derived tissue refers to tissue obtained from the patient's cancer cells or cells that are beginning to transform into cancer cells, with the composition of proteins (including peptides) identified. For example, cancer cells or cells that are transforming into cancer cells have mutated gene structures that are not found in other normal cells, and this can be used as a method for identification.

[0163] Thus, cancer antigens generated from patient-derived tissue, unlike artificial antigens, are optimal as markers for cancer in that particular patient, and therefore, a high level of effectiveness can be expected. <Embodiment 8: Mainly corresponding to claim 8 - Processing flow>

[0164] Figure 9 is a flowchart showing the procedure of Embodiment 8. Steps that overlap with other embodiments will not be described, and only the different steps will be described. The ligand generation step 0912 is performed in parallel with the preparation step 0901, the component blood collection step 0902, and the splitting step 0903, and must be completed at least before the pulse step 0904 is performed. In this ligand generation step, a ligand is generated based on the patient's own biological information, and this ligand is used in the pulse step on at least one of the immature dendritic cells that have been split into multiple groups. In this way, one or more of the multiple dendritic cell vaccines that make up the cocktail dendritic cell vaccine are generated based on the patient's own biological information. <Embodiment 8: Mainly corresponds to claim 8. Effects>

[0165] According to this embodiment, since one of the dendritic cell vaccines constituting the cocktail dendritic cell vaccine uses a cancer antigen generated based on the patient's own biological information (patient-derived tissue), reliable efficacy can be expected. <Embodiment 9: Mainly corresponds to claim 9 - Summary>

[0166] Embodiment 9 generates cancer antigens based on the individual patient's biological tissue and uses them as ligands. <Embodiment 9: Configuration mainly corresponding to claim 9>

[0167] Embodiment 9 is a method for producing a cocktail dendritic cell vaccine, comprising, in addition to the configuration of any one of Embodiments 1 to 8, a filling step of filling an injection device (including, but not limited to, a syringe; the same applies hereinafter) with the stored ligands after the storage period into an injection device (including, but not limited to, a syringe) for returning each pulsed group of ligands to the patient's body in group units. <Embodiment 9: Mainly corresponds to claim 9. Configuration: Filling step>

[0168] A single dose may consist of one storage container, or in some cases, multiple containers may be needed for one dose. However, one syringe or similar device is used for each administration, and the appropriate dose is filled into it. <Embodiment 9: Mainly corresponding to claim 9 - Processing flow>

[0169] Figure 10 is a flowchart showing the procedure of Embodiment 9. Steps that overlap with other embodiments will not be explained, and only the different steps will be described. The filling step 1013 is the step of thawing the dendritic cell vaccine, which was stored in a storage container and frozen in the storage step 1005, for a single dose, and filling it into a syringe or the like. The cocktail dendritic cell vaccine thus filled into the syringe or the like is administered to the patient. <Embodiment 10: Mainly corresponds to claim 10 - Summary>

[0170] Embodiment 10 is a method for producing a cocktail dendritic cell vaccine, comprising any one of Embodiments 1 to 9, characterized in that the ligand used in the ligand pulse step is two or more ligands selected from WT1 peptide, neoantigen, and α-galactosylceramide. <Embodiment 10: Primarily corresponds to claim 10. Details>

[0171] As explained in the ligand selection step above, the WT1 peptide is a protein structure expressed in almost all cancers, and is expected to be effective in a wide range of cancer sites and patients. On the other hand, neoantigens can be expected to be highly effective because they use tissue that expresses the neoantigen in the patient's cancer, but they have problems in terms of time and cost because it is necessary to analyze the patient's own tissue and identify the structure. For this reason, neoantigens are more likely to be used in patients who have the financial means, and they may be used alone or in combination with the WT1 peptide. As for alpha-galactosylceramide, it is likely to be administered to most patients, and high efficacy can be expected when used in combination with the WT1 peptide or neoantigen. <Embodiment 10: Configuration corresponding to claim 10>

[0172] The configuration of Embodiment 10 is the same as the configuration of any one of Embodiments 1 to 9. <Embodiment 10: Mainly corresponds to claim 10 - Processing flow>

[0173] The processing flow of Embodiment 10 is the same as the processing flow of any one of Embodiments 1 to 9. In the ligand pulse step, the ligands pulsed are two or more ligands selected from WT1 peptide, neoantigen, and α-galactosylceramide to produce a cocktail dendritic cell vaccine. <Embodiment 10: Mainly corresponds to claim 10. Effects>

[0174] According to this embodiment, by using a specific immunodendritic cell vaccine that uses WT1 peptide, which is highly likely to be effective against various cancers in many people, as a ligand, and a non-specific immunodendritic cell vaccine that uses α-galactosylceramide, which is compatible with and expected to be effective in almost anyone, a high anti-cancer effect can be expected against various cancers in many people. [Explanation of Symbols]

[0175] 0201 Action of alpha-galactosylceramide-pulsed dendritic cell vaccine 0202 Promotes the maturation of dendritic cells 0203 Adjuvant action 0204 Apoptosis induction effect on cancer cells 0205 Checkpoint Inhibition 0206 Inhibitory effect on angiogenesis 0210 Cancer antigen presentation effect 0211 Order to attack cancer cells 0212 Instructions for antibody production against cancer antigens 0213 Killer T cell attack on cancer cells 0214 Destructive effect on neovascularization 0220 NK cell attack on cancer cells 0221 Antigen presentation by dendritic cells 0222 Macrophage cancer antigen presentation 0223 Cancer antibody production effect 0224 Phagocytosis of cancer cells by macrophages

Claims

1. A cocktail dendritic cell vaccine comprising a combination of a first dendritic cell vaccine and a second dendritic cell vaccine, The first dendritic cell vaccine comprises first mature dendritic cells obtained by pulsing a first group of immature dendritic cells with a ligand that activates NKT cells and culturing the pulsating group of immature dendritic cells, the second dendritic cell vaccine comprises second mature dendritic cells obtained by pulsing a second group of immature dendritic cells with an artificially generated or identified cancer antigen and culturing the resulting cells; the first group of immature dendritic cells and the second group of immature dendritic cells are prepared by dividing monocytes collected from a patient who is ready for blood component collection in one course of blood collection into a plurality of groups, and then differentiating each group of monocytes into immature dendritic cells, or by dividing immature dendritic cells differentiated from monocytes collected from a patient in one course of blood collection into a plurality of groups; A cocktail dendritic cell vaccine, in which the first dendritic cell vaccine and the second dendritic cell vaccine are administered to the patient simultaneously so as to be effective in the body.

2. A cocktail dendritic cell vaccine as described in claim 1, wherein the first dendritic cell vaccine and the second dendritic cell vaccine are mixed in advance and then administered.

3. The cocktail dendritic cell vaccine described in claim 1, wherein the first dendritic cell vaccine and the second dendritic cell vaccine are administered individually, one type at a time.

4. A cocktail dendritic cell vaccine described in any one of claims 1 to 3, wherein the ligand that activates NKT cells is alpha-galactosylceramide, and the cancer antigen is a WT1 peptide or a neoantigen, or both.

5. A method for producing the cocktail dendritic cell vaccine of claim 1, comprising: A preparation step of collecting a predetermined amount of monocytes from a patient who is ready for blood component collection in one course of blood collection; a dividing step of dividing monocytes obtained by blood component collection only from the patient into a plurality of groups, and then differentiating each group of monocytes into immature dendritic cells, or dividing immature dendritic cells differentiated from monocytes obtained by blood component collection only from the patient into a plurality of groups; a pulsing step in which at least one of the groups divided in the division step, a first group of immature dendritic cells, is pulsed with a ligand that activates NKT cells, and the remaining second group of immature dendritic cells is pulsed with an artificially generated or identified cancer antigen as a ligand, and cultured to mature the first and second mature dendritic cells, respectively; storing the ligand-pulsed mature dendritic cells of each group; A manufacturing method comprising:

6. an immunity / disease information acquisition step for acquiring, before the preparation step, one or more of immunity information, which is information regarding the immunity of a patient, biological information of an individual patient, and disease information of a patient; The method for producing a cocktail dendritic cell vaccine according to claim 5, further comprising a ligand selection step in which the ligand pulsed in the pulsing step is selected according to the acquired immunity / disease information.

7. The method for producing a cocktail dendritic cell vaccine according to claim 6, further comprising a division ratio determination step in which the division ratio in the division step is determined based on the acquired immunity / disease information.

8. The method for producing a cocktail dendritic cell vaccine described in claim 6 or 7, further comprising a storage period determination step in which the storage period for each group in the storage step is determined based on the acquired immunity / disease information.

9. Further comprising an observation result acquisition step of observing each group pulsed with the ligand after the pulsing step to obtain an observation result; A method for producing a cocktail dendritic cell vaccine described in any one of claims 5 to 8, wherein the storage period for each group in the storage step is further determined based on the observation results obtained in the observation result obtaining step.

10. A method for producing a cocktail dendritic cell vaccine described in any one of claims 5 to 9, further comprising a freezing / refrigerating storage step of freezing or refrigerating at least one of each group divided between the division step and the pulsing step.

11. A method for producing a cocktail dendritic cell vaccine described in any one of claims 5 to 10, further comprising a ligand generation step of generating a ligand based on an individual patient's body tissue, and the pulse step is configured to pulse the ligand generated in the ligand generation step.

12. A method for producing a cocktail dendritic cell vaccine described in any one of claims 5 to 11, further comprising a filling step of filling each group pulsed with the stored ligand after the storage period into an injection device (including but not limited to a syringe; the same applies below) for returning each group to the patient's body on a group-by-group basis.

13. A method for producing a cocktail dendritic cell vaccine described in any one of claims 5 to 12, characterized in that the ligand pulsed in the pulse step is alpha-galactosylceramide as a ligand that activates NKT cells, and the ligand used as a cancer antigen is a WT1 peptide or a neoantigen, or both.